Asia-Pacific Journal of Clinical Oncology· 2026Q2
Opioid Prescribing Changes in Advanced Cancer Before and After Withdrawal of Hydromorphone Slow‐Release Tablets
- 0citations
- Q2SCImago
- 2026year
Short summary
Following the withdrawal of hydromorphone slow-release (SR) tablets in Australia, prescribing patterns for advanced cancer pain shifted, with methadone use increasing by 42% (aOR 1.42) and its median dose doubling (45 mg vs. 22.5 mg), while morphine use declined (aOR 0.69).
AI-generated from the title and abstract; the full text is not read.
Key points
- Hydromorphone SR tablet withdrawal in Australia led to a 42% increase in methadone use (aOR 1.42) among advanced cancer patients.
- The median dose of methadone doubled from 22.5 mg to 45 mg post-withdrawal (p = 0.005).
- Morphine use decreased (aOR 0.69, p < 0.001), but daily opioid equivalent doses increased by ~20%.
- Prescribing of tapentadol (aOR 1.40) and buprenorphine (aOR 1.37) also increased without dose escalation.
AI-generated from the title and abstract; the full text is not read.
Abstract
AIM: Ongoing disruptions to opioid supply in Australia have raised ongoing concerns about their impact on cancer pain management. The withdrawal of hydromorphone slow-release (SR) tablets from the Australian market has presented challenges to advanced cancer pain management. This study aimed to determine how this affected the utilisation of alternative slow-release opioids in patients with advanced cancer. METHODS: A retrospective cohort study was conducted at a quaternary cancer centre, comparing opioid prescribing patterns across two 12-month periods: before hydromorphone SR tablet discontinuation was announced and after its discontinuation. Inpatient and outpatient prescribing data were analysed for adult patients with incurable advanced or metastatic cancer who first presented to the centre during each study period. RESULTS: A total of 2856 patients were included (n = 1475 pre and n = 1381 post hydromorphone SR discontinuation). Following hydromorphone SR withdrawal, opioid prescribing patterns shifted. Methadone use rose modestly (adjusted odds ratio [aOR] 1.42, p = 0.07), accompanied by a doubling of median dose (45 mg vs. 22.5 mg; p = 0.005). Morphine use declined (aOR 0.69, p < 0.001), yet daily OMEDD increased by ∼20% (95% confidence interval 1.01-1.37). Tapentadol (aOR 1.40, p = 0.01) and buprenorphine (aOR 1.37, p < 0.001) were prescribed more frequently, without corresponding dose escalation. CONCLUSIONS: Following hydromorphone SR withdrawal, the frequency of methadone use increased and median doses doubled. Research incorporating national datasets is needed to clarify the broader impact of opioid supply interruptions. These findings indicate a potential need to reframe the place of methadone in practice, and potentially upscale the focus of clinician training on its safe and effective use.
The authors' abstract, as published at the source. Asia-Pacific Journal of Clinical Oncology, 2026 · DOI ↗
Continue with a free account
Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.
Continue free on the webSign in with Google or Apple; no card needed. You come back to this paper.
On your phone:
Field: Anesthesiology and Pain Medicine
Anesthesiology and Pain MedicineMedicine